How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Cristiana Toader
Advertisement
Cristiana Toader is Manager at Executive Insight.
Articles by Cristiana Toader
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
WHO Finalizes United States’ Withdrawal from Organization: Report
2
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
3
From Evidence to Access: How Real-World Data Delivers for Patients
4
Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics
5